PT - JOURNAL ARTICLE AU - Guijarro, Carlos AU - Galán, Isabel AU - MartÍnez-Ponce, Diana AU - Pérez-Fernández, Elia AU - Goyanes, Maria José AU - Castilla, Virgilio AU - Velasco, MarÍa TI - SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine AID - 10.1101/2021.03.24.21254238 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.24.21254238 4099 - http://medrxiv.org/content/early/2021/06/03/2021.03.24.21254238.short 4100 - http://medrxiv.org/content/early/2021/06/03/2021.03.24.21254238.full AB - Objectives To evaluate the effect of mRNA SARS-Cov-2 vaccination on the incidence of new SARS-CoV-2 infections in health care workers (HCW).Methods The evolution of the incident rate of microbiologically confirmed SARS-CoV-2 infection in a cohort of 2590 HCW after BNT162b2 mRNA SARS-CoV-2 vaccination, as compared to the rate in the community (n=170513) was evaluated by mixed Poisson regression modelsResults A total of 1820 HCW (70,3% of total) received the first dose of the BNT162b2 mRNA vaccine between January 10-16, 2021), and 296 (11,4%) the following week. All of them completed vaccination 3 weeks later. Incidence rates of SARS-CoV-2 infection after the first dose of mRNA SARS-CoV-2 vaccine declined by 71% (Incidence Rate Ratio (IRR) 0.286, 95% confidence interval (CI) 0.174-0.468, p< 0.001) and by 97% (IRR 0.03 95% CI 0.013-0.068, p<0.001) after the second dose as compared to the perivaccine time. SARS-CoV-2 incidence rates in the community (with a negligible vaccination rate) had a much lower decline: 2% (IRR 0.984; 95% CI 0.943-1.028; p = 0.47) and 61% (IRR 0.390, 95% CI 0.375-0.406; p<.001) for equivalent periods. Adjusting for the decline in the community, the reduction in the incident rates among HCW were 73% (IRR 0.272; 95% CI 0.164-0.451 p<0.001) after the first dose of the vaccine and 92 % (IRR 0.176, 95% CI 0.033-0.174; p<0.001) after the second dose.Conclusions mRNA SARS-CoV-2 vaccination is associated with a dramatic decline in new SARS-CoV-2 infection among HCW, even before the administration of the second dose of the vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The estudy was apprroved by the Independent Review Board - Ethics Committee for Drug Research of Hospital Universitario Fundacion Alcorcon. HCW signed informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request